Health Catalyst - HCAT Stock Forecast, Price & News

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JPMorgan Chase & Co. cut Health Catalyst from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $20.00 to $16.00 in a research note on Friday, August 5th. The Goldman Sachs Group reduced their target price on Health Catalyst from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday. Royal Bank of Canada reduced their price objective on Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Citigroup reduced their price objective on Health Catalyst from $45.00 to $25.00 in a research note on Wednesday, May 11th. Finally, BTIG Research reduced their price objective on Health Catalyst from $35.00 to $25.00 in a research note on Wednesday, July 27th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $26.69.

Health Catalyst Trading Up 1.8 %

Health Catalyst stock opened at $12.83 on Friday. The firm has a 50-day moving average of $15.12 and a 200-day moving average of $20.17. The firm has a market cap of $702.10 million, a P/E ratio of -4.38 and a beta of 1.14. Health Catalyst has a 1-year low of $10.95 and a 1-year high of $57.19.

Health Catalyst (NASDAQ:HCAT - Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.03. Health Catalyst had a negative net margin of 54.64% and a negative return on equity of 18.31%. The company had revenue of $68.09 million during the quarter, compared to analyst estimates of $66.01 million. During the same period in the prior year, the business posted ($0.37) earnings per share. Health Catalyst's revenue for the quarter was up 21.9% on a year-over-year basis. Research analysts forecast that Health Catalyst will post -1.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 1,860 shares of the firm's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the completion of the sale, the insider now directly owns 60,173 shares in the company, valued at $954,945.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Health Catalyst news, General Counsel Daniel H. Orenstein sold 2,838 shares of the firm's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the completion of the sale, the general counsel now directly owns 103,671 shares in the company, valued at $1,539,514.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Linda Llewelyn sold 1,860 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares of the company's stock, valued at $954,945.51. The disclosure for this sale can be found here. Insiders sold 6,255 shares of company stock worth $93,877 over the last three months. Company insiders own 1.50% of the company's stock.